Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefiderocol versus meropenem for Gram-negative hospital-acquired, ventilator-associated, or healthcare-associated bacterial pneumonia
2016-003020-23Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and bacterial pneumonia comparing Cefiderocol with Meropenem (2 arms). Primary endpoint: All-cause mortality at Day 14. Started Aug 2017; status: completed.
02
Drugs
cefiderocolmeropenem
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)bacterial pneumonia
Beyond the preview
Go deeper on 2016-003020-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003020-23.